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Introduction
Myocardial salvage (MS) can be assessed retrospectively
by T2-weighted and delayed enhancement images as
shown in animal studies. Currently there is limited data in
humans and this technique has not been used for the
assessment in multicenter trials comparing different
reperfusion regimens in STEMI. Facilitated PCI with fibri-
nolysis did not show a benefit in comparison to primary
PCI in recently published trials. However, a subgroup of
high-risk STEMI patients presenting early after symptom
onset, treated with optimal antiplatelet co-medication,
and with long transfer times might benefit from a fibrino-
lytic-based facilitated PCI.
Purpose
Aim of this trial was to establish MS imaging as a surrogate
endpoint in a randomized multicenter trial and to show
that facilitated PCI versus primary PCI in a STEMI network
with long transfer distances up to 70 km is beneficial with
respect to infarct size (IS) and MS.
Methods
Patients with STEMI (<3 h after symptom onset) were ran-
domized to either prehospital initiated facilitated PCI
using tenecteplase (group A; n = 81) or primary PCI
(group B; n = 81). Optimal prehospital co-medication
consisted of 600 mg clopidogrel loading-dose plus aspi-
rin. The primary endpoint was IS assessed by delayed
enhancement. Secondary endpoints were microvascular
obstruction and MS assessed by MRI, ST-resolution at 90
min., and a composite of death, re-MI, and congestive
heart failure at 30 day follow-up.
Results
All images were assessable for the calculation of the MS
index. The median time from symptom-onset to randomi-
zation was 64 min (IQR 42;103) in group A versus 55 min
in group B (IQR 27;91; p = 0.26). Despite better preinter-
ventional TIMI-flow in group A (76% versus 28% TIMI 2
or 3; P < 0.001) IS size was similar in group A versus B
(14.1% of left ventricle [IQR 5.3;26.7] versus 15.1% [IQR
7.5;23.3]; p = 0.75). There was also no difference in
microvascular obstruction, MS (p = 0.65 and 0.71) and a
trend towards worse ST-segment resolution (p = 0.07).
The combined clinical endpoint showed a trend towards
higher event rates in group A (18.9% versus 8.1%; p =
0.09, relative risk 2.33, 95% confidence interval, 0.98-
5.63).
Conclusion
MRI can reliably measure MS retrospectively and served as
a surrogate endpoint in this randomized multicenter clin-
ical trial. This trial failed to show that in patients with
STEMI - presenting early after symptom onset with rela-
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tively long transfer times - a fibrinolytic-based facilitated
PCI approach with optimal antiplatelet co-medication
offers any benefit over primary PCI with respect to IS and
tissue perfusion.Page 2 of 2
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